Virtual Library

Start Your Search

G. An



Author of

  • +

    Best abstracts selected from submissions 7 (ID 5)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/09/2018, 16:20 - 17:00, Jade Ballroom
    • +

      OA13 - High-dose Icotinib in Advanced NSCLC with EGFR 21 L858R Mutation: A Randomized, Open-Label Phase II Study (ID 211)

      16:20 - 17:00  |  Author(s): G. An

      • Abstract
      • Slides

      Background:
      NSCLC patients with 21 L858R mutation are less responsive to EGFR TKI treatment. This study aims to determine if high-dose icotinib can improve tumor response and progression-free survival (PFS) in this patient population.


      Method:
      In this randomized, open-label, multicenter phase II trial (INCREASE), patients with treatment-na

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.